License Revenue - Related Party was Dianthus Therapeutics’s largest product and service line in fiscal 2024, bringing in $5.91M of $6.24M (95%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Zenas Biopharma Limited | $6.40M | — | — |
| License Revenue - Related Party | — | $2.83M | $5.91M |
| Nonrelated Party | — | — | $326.00K |
| Total | $6.40M | $2.83M | $6.24M |
Dianthus Therapeutics brought in $6.24M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. Dianthus Therapeutics regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $2.83M. License Revenue - Related Party was the largest at $5.91M (94.8%), ahead of Nonrelated Party at $326.00K (5.2%).
Dianthus Therapeutics began breaking out License Revenue - Related Party in fiscal 2023 and Nonrelated Party in fiscal 2024. Dianthus Therapeutics stopped reporting Zenas Biopharma Limited as a separate line after fiscal 2022, when it brought in $6.40M.
Dianthus Therapeutics (DNTH) reports its revenue by product and service. In fiscal 2024, License Revenue - Related Party was its largest product and service line, bringing in $5.91M (94.8% of the total), followed by Nonrelated Party at $326.00K (5.2%).
License Revenue - Related Party was Dianthus Therapeutics' largest product and service line in fiscal 2024, bringing in $5.91M, or 94.8% of the $6.24M total across its two product and service lines.
Every figure comes from Dianthus Therapeutics' annual financial filings, as reported. Each line keeps the name Dianthus Therapeutics gives it, and years follow its fiscal calendar.
Dianthus Therapeutics' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.